Medicinal Herbals with Antiplatelet Properties Benefit in Coronary Atherothrombotic Diseases

Nurul Huda Mohd Nor1, Fauziah Othman1, Eusni Rahayu Mohd Tohit2

  • 1Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43000 Serdang, Selangor, Malaysia.

Thrombosis
|April 7, 2016
PubMed

Insights

This review explores traditional medicinal plants with antiplatelet properties to combat atherothrombotic diseases. Research into these natural compounds offers potential alternatives to conventional drugs like aspirin and clopidogrel.

Area of Science:

  • Pharmacology and Herbal Medicine
  • Cardiovascular Research
  • Thrombosis and Hemostasis

Background:

  • Coronary atherothrombotic diseases pose significant health risks, with thrombus formation in blood vessels being a primary concern.
  • Current management relies on anticoagulant and antiplatelet drugs, including dual antiplatelet therapy (aspirin and clopidogrel), to prevent disease recurrence.
  • Challenges such as aspirin resistance and poor compliance with dual antiplatelet regimens necessitate the exploration of alternative therapeutic strategies.

Purpose of the Study:

  • To review traditional antithrombotic medicinal plants and their investigated antiplatelet properties.
  • To highlight the potential of herbal compounds as alternative or complementary treatments for atherothrombotic conditions.
  • To identify areas for further research into the in vitro and in vivo antiplatelet effects of traditional herbs.

Main Methods:

  • Literature review of traditional medicinal plants used for heart diseases.
  • Analysis of studies investigating the antiplatelet properties of selected herbs.
  • Examination of in vitro and in vivo evidence for the efficacy of these herbal agents.

Main Results:

  • Several traditional herbs exhibit antiplatelet properties, suggesting potential therapeutic value.
  • These natural compounds may offer an alternative approach to managing thrombosis.
  • The review consolidates existing research on the antiplatelet mechanisms of these medicinal plants.

Conclusions:

  • Medicinal plants represent a promising source for novel antithrombotic agents.
  • Further in-depth research is warranted to fully elucidate the antiplatelet potential and clinical applications of traditional antithrombotic herbs.
  • Exploring these natural resources could lead to improved management strategies for cardiovascular diseases.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
395
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
543
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
408
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K